126 related articles for article (PubMed ID: 1902201)
1. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Takai S; Yamamura M; Tanaka K; Kawanishi H; Tsuji M; Nakane Y; Hioki K; Yamamoto M
Int J Cancer; 1991 Apr; 48(1):20-7. PubMed ID: 1902201
[TBL] [Abstract][Full Text] [Related]
2. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasminogen activators and stomach carcinoma stage.
Umehara Y; Kimura T; Yoshida M; Oba N; Harada Y
Acta Oncol; 1991; 30(7):815-8. PubMed ID: 1764272
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
de Bruin PA; Verspaget HW; Griffioen G; Verheijen JH; Dooijewaard G; Lamers CB
Br J Cancer; 1989 Sep; 60(3):397-400. PubMed ID: 2506920
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Sier CF; Verspaget HW; Griffioen G; Ganesh S; Vloedgraven HJ; Lamers CB
Gut; 1993 Jan; 34(1):80-5. PubMed ID: 8432457
[TBL] [Abstract][Full Text] [Related]
8. [The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator].
Hata M
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1558-65. PubMed ID: 2512407
[TBL] [Abstract][Full Text] [Related]
9. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor 1 in human carcinoma tissues.
Tanaka N; Fukao H; Ueshima S; Okada K; Yasutomi M; Matsuo O
Int J Cancer; 1991 Jun; 48(4):481-4. PubMed ID: 1904404
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats.
Andreasen PA; Kristensen P; Lund LR; Danø K
Endocrinology; 1990 May; 126(5):2567-76. PubMed ID: 2109689
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of urokinase-type plasminogen activator in Sertoli cells and tissue-type plasminogen activator in spermatogenic cells in the rat seminiferous epithelium.
Vihko KK; Kristensen P; Danø K; Parvinen M
Dev Biol; 1988 Mar; 126(1):150-5. PubMed ID: 3125078
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Cancer; 1996 Mar; 77(6):1035-43. PubMed ID: 8635120
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
17. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
18. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin.
Grøndahl-Hansen J; Ralfkiaer E; Nielsen LS; Kristensen P; Frentz G; Danø K
J Invest Dermatol; 1987 Jan; 88(1):28-32. PubMed ID: 3098860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
